{
    "clinical_study": {
        "@rank": "4727", 
        "acronym": "REEF-CMH", 
        "arm_group": {
            "arm_group_label": "single group - consecutive patients", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to demonstrate that changes in plasma levels of\n      circulating neurohormones (mainly BNP and NT-proBNP), measured at rest and post-exercise\n      correlate with exercise  functional limitation (assessed by exercise peak VO2) and exercise\n      ultrasonic parameters (as left ventricular filling, obstruction, and mitral regurgitation)"
        }, 
        "brief_title": "Neurohormonal Parameters in Hypertrophic Cardiomyopathies", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy", 
            "2- Obstructive Hypertrophic Cardiomyopathy", 
            "3- Non Obstructive Hypertrophic Cardiomyopathy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiomyopathy, Hypertrophic", 
                "Hypertrophy", 
                "Cardiomyopathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "The secondary purposes are to study the kinetics of secretions of natriuretic peptides, and\n      their relationships with extent of MRI myocardial fibrosis with the degree of exercise\n      functional limitation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  - Age 18 to 75 years\n\n          -  Primary (sarcomeric) hypertrophic cardiomyopathy, obstructive or non obstructive,\n             with studies of exercise peak oxygen consumption and cardiac MRI with gadolinium\n             late-enhancement\n\n          -  Informed consent\n\n          -  Patient with a social insurance Patient at rest\n\n          -  - Age 18 to 75 years\n\n          -  Primary (sarcomeric) hypertrophic cardiomyopathy, obstructive or non obstructive\n\n          -  Informed consent\n\n          -  Patient with a social insurance\n\n        Exclusion Criteria:\n\n          -  - Insufficient echogenicity\n\n          -  Permanent atrial fibrillation\n\n          -  Complete BBB on the ECG\n\n          -  LVEF < 35 %\n\n          -  Previous septal ablation (surgical or percutaneous)\n\n          -  Simultaneous participation to another biomedical research\n\n        If exercise needed:\n\n          -  contraindication to exercise : hemodynamic instability, uncontrolled high blood\n             pressure (>220/120 mmHg), severe aortic stenosis\n\n          -  Inability to exercise (muscular, pulmonary, elderly patient)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "131", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01729702", 
            "org_study_id": "2008-08"
        }, 
        "intervention": {
            "arm_group_label": "single group - consecutive patients", 
            "intervention_name": "blood sample collection", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "1- Hypertrophic cardiomyopathy", 
            "2- BNP", 
            "3- NT-proBNP", 
            "4- Neurohormons"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75015"
                }, 
                "name": "H\u00f4pital Europ\u00e9en Georges Pompidou"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation at Rest and Exercise of Clinical, Ultrasonic and Neurohormonal Parameters in Hypertrophic Cardiomyopathies", 
        "overall_official": {
            "affiliation": "HEGP - Paris", 
            "last_name": "Albert Hag\u00e8ge, MD-PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France:Agence Nationale de S\u00e9curit\u00e9 des M\u00e9dicaments", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Plasmatic Neurohormonal measures: BNP - NT ProBNP - Troponine", 
            "safety_issue": "No", 
            "time_frame": "Day 1 at rest and during exercise"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01729702"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "French Cardiology Society", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "French Cardiology Society", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2009", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}